Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization

Hepatocellular carcinoma

(2012) Alejandro Forner et al.   LANCET

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

(2011) Roopinder Gillmore et al.   JOURNAL OF HEPATOLOGY

Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009)

(2010) Shigeki Arii et al.   HEPATOLOGY RESEARCH

The resurrection of alphafetoprotein

(2010) Morris Sherman   JOURNAL OF HEPATOLOGY

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Significance of Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy

(2009) Kentaroh Yamamoto et al.   ANNALS OF SURGICAL ONCOLOGY

Complete Necrosis After Transarterial Chemoembolization Could Predict Prolonged Survival in Patients with Recurrent Intrahepatic Hepatocellular Carcinoma After Curative Resection

(2009) Ju Hyun Shim et al.   ANNALS OF SURGICAL ONCOLOGY

High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma

(2009) Masahiro Kobayashi et al.   CANCER

Des-γ-Carboxy Prothrombin and α-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma

(2009) Anna S. Lok et al.   GASTROENTEROLOGY

Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival

(2009) Ahsun Riaz et al.   JOURNAL OF CLINICAL ONCOLOGY

New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

(2008) Stephen L. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute